Method and Its pharmacdutical composition ofex vivo expansions of Natural killer cells and Natural Killer T-Cells.
1.August 21,2019 Invention patent certificate of the Republic of China No.1669399
2.November 25, 2022 Certificate of Invention Patent in China Ref No. CN110628715B
Serum-free cell culture medium for in vitro amplification of natural killer cells and natural killer T cells
1. Taiwan Invention Patent Certificate No. I669400, August 21, 108
2. On March 28, 2023, Mainland China Invention Patent Certificate Authorization Announcement No.: CN110628714B
Serum free cryopreservation solution for cell cryopreservation
1. 2022 Taiwan Patent Certificate Invention No. I783317
CELL THERAPY CENTER IN CHINA
The allogeneic immune cell preparation PB103 will achieve "global brand, all-round service" as the goal, with Shenzhen Dapeng as the cell production base, establish cell therapy centers in various provincial cities, and successfully expand the inland immune cell therapy market hinterland..
Cell Therapy Center
Chengdu Cell Therapy Center | Chongqing Cell Therapy Center | Changsha Cell Therapy Center | Nanning Cell Therapy Center |
Guangzhou Cell Therapy Center | Shenzhen Cell Therapy Center | Beijing Cell Therapy Center | Zhengzhou Cell Therapy Center |
Xi'an Cell Therapy Center | Wuhan Cell Therapy Center | Tianjin Cell Therapy Center | Nanjing Cell Therapy Center |
Shanghai Cell Therapy Center | Hangzhou Cell Therapy Center | Suzhou Cell Therapy Center | Fuzhou Cell Therapy Center |
Shenzhen Cell Production Base |
HANGZHOU PROTISTA BIOTECHNOLOGY CELL DEVELOPMENT AND PRODUCTION CENTER
Precision Biotechnology International wholly owns Hangzhou Native Biotechnology Co., Ltd., which was established in February 2018 with a factory building of 1,600 square meters meeting GMP standard, and located in XiaoShan Economic & Technological Development Zone, Hangzhou. It was designed according to GMP standards, and the production area of cell preparation center adopts Class A aseptic isolation system. It is the first enterprise in China to adopt aseptic fully isolated closed system, which lays a foundation for the automation and artificial intelligence of cell proliferation and culture, realizing the whole dynamic 100-level operation process of cell therapy products. Native Biotechnology ’s GMP laboratory and cell preparation center can fully meet the production demand of allogeneic natural killer immune cell preparations PB103 in clinical trials.
CELL PRODUCTION BASE AND CELL THERAPY CENTER
Precision Biotech has established R&D and cell production bases, cell freezing centers, cell therapy centers, radio therapy centers, thermotherapy centers, anti-aging treatment centers, and special intelligent cancer specialized hospitals in Dapeng New District, Shenzhen, and at the same time carried out phase I/II clinical trials of allogeneic natural killer immune cell PB103 preparations in China and also carrying out Breakthrough Therapy Drug Program in China therefore the product can be marketed in advance; it is expected that Breakthrough Therapy Drug Program can be done by the end of 2025 and rapidly enter the China market and saving more lives and patients with stage IV non-small cell lung cancer.
Precision Biotech owns cell storage preparation centers and production bases in Taiwan, Shenzhen and Hangzhou, that meet GMP and FDA international top standards,completed biological laboratories and quality and safety assurance systems. Established a production quality management system in line with GMP standards, the laboratory is equipped with sterile full isolation closed system, isolator, incubator, centrifuge, flow cytometer, microbial identification instrument and other production and quality inspection equipment, Aseptic operation in Class A environment to effectively prevent product contamination; At the same time, the company adopts mycoplasma examination method, rapid sterility examination method and other cell product quality control methods to solve the key technical problems of large-scale production and quality inspection of immune cell drugs, and realize the standardization and industrial production of immune cell drugs.